capivasertib,AZD5363
astrazeneca,otsuka
['mbc', 'capivasertib']
faktion: fulvestrant+/- capivasertib in hr+ mbc now with 58 mo f/u, pfs 4.8vs10.3mo, os 23.4vs 29.3, both statistically significant, in pathway altered group (54% of pts) pfs 4.6 vs 12.8 mo, in non- altered not significant, os also sig in pathway altered group #asco22 
Chief, Division of Breast Oncology @DanaFarber
Tennis fan
Mother of two teenage girls